The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...

Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health ...

Don’t tell Neil Armstrong, but giant leaps for mankind may leave astronauts feeling a little queasy. In a new experiment, aerospace engineers at the University of Colorado Boulder will work with ...

My first experience with motion sickness was as a college student, standing on the back of a marine research vessel looking at interesting things dredged from the seafloor off the California coast. It ...

Motion sickness sufferers will know all too well how feelings of nausea can linger even after movement has stopped. But researchers in China may have found a way to speed up recovery — listen to happy ...